Skin barrier function repair

Skin barrier function repair refers to the physiological and therapeutic process of restoring the integrity of the epidermal permeability barrier, primarily located in the stratum corneum. This barrier is often described by the 'bricks-and-mortar' model, where protein-rich corneocytes are embedded in a complex lipid matrix consisting of ceramides, cholesterol, and free fatty acids (PMID: 24656726). The primary biological function of this barrier is to maintain homeostasis by preventing excessive transepidermal water loss (TEWL) and shielding the body from exogenous pathogens, allergens, and chemical irritants (PMID: 19126444). Barrier dysfunction is a central feature of inflammatory skin diseases like atopic dermatitis, where genetic deficiencies in structural proteins like filaggrin or the presence of Th2-type cytokines (IL-4 and IL-13) lead to a compromised seal (PMID: 23114871). Pharmacological strategies to repair the skin barrier include the topical application of physiological lipids to replenish the intercellular matrix and the use of targeted anti-inflammatory agents to prevent cytokine-mediated barrier degradation. Modern therapies, such as the monoclonal antibody dupilumab, indirectly support barrier repair by blocking the signaling of cytokines that downregulate the production of essential barrier proteins (PMID: 25773215). Clinical monitoring of repair efficacy is typically performed using non-invasive measures of TEWL and skin hydration levels. Successfully repairing the skin barrier is a critical clinical goal for reducing disease flares and preventing the systemic sensitization associated with the atopic march.

Other names

Epidermal barrier functionPermeability barrier maintenanceStratum corneum barrier integritySkin barrier homeostasisCutaneous barrier repair

Restoration of the lipid bilayer (ceramides, cholesterol, and fatty acids), enhancement of structural protein expression (e.g., filaggrin and involucrin), and inhibition of Th2-mediated cytokine pathways (IL-4/IL-13) that suppress barrier protein synthesis.